Expanded access to sevabertinib for HER2-mutated lung cancer
Part of Cancer clinical trials.
This trial provides access to an investigational pill called sevabertinib (BAY 2927088) for people with advanced non-small cell lung cancer that has a HER2 mutation. It aims to see if this medication can help control the cancer when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced non-small cell lung cancer (NSCLC) with a specific change called a HER2 mutation.
- Your cancer has progressed after at least one prior treatment for advanced disease.
- You are generally feeling well enough to care for yourself (able to do light activities like walking or light housework).
- You can take pills by mouth.
- You are not currently pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
This study tests an oral tablet called sevacertinib in people with solid tumors (not lung cancer) that have a HER2 mutation. It aims to see how well the drug works and how safe it is for people who have tried other treatments or have no good options left.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
This trial tests a new targeted therapy (vebreltinib plus PLB1004) against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation) and MET protein, and has stopped responding to earlier EGFR treatment.
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.